Theme: Latest discoveries and innovations in the field of Molecular and Cancer Biomarkers

Molecular Biomarkers 2016

Molecular Biomarkers 2016

Conference Series LLC invites all the participants from all over the world to attend '7th International Conference and Expo on Molecular & Cancer Biomarkers' during September 15-16, 2016 in Berlin, Germany which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Molecular Biomarkers 2016 is a platform to discuss and learn about the latest advancements in the field of Molecular and Cancer Biomarkers. Biomarkers have been a great tool in the new generation diagnosis, prognosis and treatment of various diseases. Molecular biomarkers include proteins, lipids, DNA, RNA and several other components in the body. Their applications in some disease pathologies have gained a prominence over period like in cancer and Alzheimer’s diseases. Advanced studies in these fields also opened up a wide scope in development of medical tools and technologies like imaging and companion diagnostics. People form American Oncology society and European Oncology society have been doing research in the field of biomarkers.

Conference Series LLC, the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe

Track 1: Molecular Biomarkers

A biomarker can be anything that can be accurately measured as an indicator of normal biological functioning, pathogenic paths or a drug response to a therapeutic drug intervention. Molecular biomarkers are the biomarkers usually in molecular form. Molecular biomarkers take part in various purposes, including disease diagnosis and prognosis, prediction and calculation of treatment response, and safety evaluation. The molecular biomarkers are exclusively being developed and validated to be used in drug development, and used to support approval of drug products.

Molecular biomarkers are mainly classified into Protein biomarkers, Nucleic acid based biomarkers, Lipid biomarkers and Small molecule biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs. There has been a rapid increase in the number of molecular biomarkers used in drug delivery over the last decade.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences:  7th Biomarkers Conference, December 05-07, 2016 Philadelphia, USA; 6th Genomics Conference, September 12-14, 2016, Berlin, Germany; 6th Pharmacogenomics Conference, September 12-14, 2016, Berlin, Germany; 8th Proteomics Conference, March 20-22, 2017, Philadelphia, USA; 12th World Cancer Conference, September 26-28, 2016, London, UK; American Association for Cancer Research Annual Meeting April 16-20, 2016, USA; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; 12th Annual Biomarkers Congress February 2017, Manchester, UK; 12th Annual Biomarkers & Diagnostics World Congress May 17-19, 2016, USA; 2nd Biomarkers Conference September 19-20, 2016, UK; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17, 2016, Paris, France; 3rd International Oncology Conference, September 10-11, 2016, UAE.

 Track 2: Cancer Biomarkers

A cancer biomarker is an element or procedure that indicates the presence of cancer in the body. A biomarker may be any molecule released by presence a tumor or a specific indication of the body to the presence of cancer. Cancer biomarkers are usually biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.

Cancer biomarkers can be classified into Nucleic acid based biomarkers, Pathological biomarkers, In silico biomarkers, Imaging biomarkers and Glycoprotein biomarkers based on their structure and functioning. All these topics are discussed in these cancer biomarkers conferences.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences12th World Cancer Conference, September 26-28, 2016, London, UK; Cancer Diagnostics Conference, June 13-15, 2016, Rome, Italy; 2nd Mass Spectrometry Conference, July 20-22, 2016 Chicago, USA; 3rd Mass Spectrometry Conference, October 10-11, 2016, Kuala Lumpur, Malaysia; 5th Medicinal Chemistry Conference, December 05-07, 2016, Phoenix, USA; ASCO Annual Meeting, June 03-07, 2016, Chicago, USA; 25th AICR Research Conference, November 14-16, 2016, North Bethesda, USA; National Cancer Institute; 3rd International Oncology Conference, September 10-11, 2016, UAE; UAE Cancer Congress, October 29-31,2 2015, UAE; Next Generation Dx Summit, August 23-24, 2016, Washington DC, USA; American Thoracic Society International Conference, May 13-18, 2016, USA; 17th World Conference on Lung Cancer December, 04-07, 2016 Austria.

Track 3: Clinical biomarkers

Biomarkers which are used for clinical purposes are called clinical biomarkers. Clinical biomarkers along with Pathological biomarkers provide a vibrant and influential methodology to understanding the range of many diseases with uses in judgemental and analytic epidemiology, arbitrary clinical trials, screening for drugs or disease diagnosis and prognosis. Defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors, and the can extend the base information about the underlying pathogenesis of disease.

The main researches in clinical biomarkers are done in the fields of drug discovery, oncology, pharmacogenomics and disease diagnostics. This biomarker meeting goes in detail about these fields.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences5th Computer Aided Drug Designing Conference, December 05-07, 2016, Phoenix, USA; 2nd Biopharmaceutics Conference, September 14-16, 2016 San Antonio, USA; 2nd Biologic Drugs Conference, September 14-16, 2016 San Antonio, USA; 2nd Genetic Engineering Conference, November 14-16, 2016, Atlanta, USA; 2nd Protein Engineering Conference, November 14-16, 2016, Atlanta, USA; European Organisation for Research and Treatment of Cancer; American Society of Clinical Oncology; Association for International Cancer Research; Asia Pacific Lung Cancer Conference May, 13-16, 2016 Thailand; American Academy of Neurology Annual Meeting April 22-29, 2017, Boston, USA;  4th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; 3rd Annual Drug Discovery USA Congress, 3-4 October 2016, San Diego, USA.

Track 4: Biomarkers and Cancers

Biomarkers play a significant role in cancer prognosis, diagnosis and treatment of cancers these days. There are many types of cancers which are hard to even diagnose. The latest designed biomarkers and their applications provide a great advantage in these cases. Cancer Epidemiology, treatment and latest research is greatly relayed on the biomarkers.

The major types of cancers in which biomarkers are widely being used are breast cancer, lung cancer, prostate cancer and blood cancer. Cancer biomarkers conferences provide a good platform for elaborated discussion on various new researches.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences2nd Protein Engineering Conference, November 14-16, 2016, Atlanta, USA; 4th Personalized Medicine Conference, September 22-24, 2016, Phoenix, USA; 4th Molecular Diagnostics Conference, September 22-24, 2016, Phoenix, USA; 5th Translational Medicine Conference, November 28-30, 2016, San Francisco, USA; 2nd Molecular Medicine Conference, September 26-28, 2016, Orlando, USA; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 03-07, 2016, Chicago, USA; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17, 2016, Paris, France; 3rd International Oncology Conference, September 10-11, 2016, UAE; UAE Cancer Congress, October 29-31,2 2015, UAE; Next Generation Dx Summit, August 23-24, 2016, Washington DC, USA; American Thoracic Society International Conference, May 13-18, 2016, USA.

Track 5: Biomarkers and Non-cancerous diseases

Biomarkers plan an important role in various neurological and cardiovascular diseases. The diseases which are incurable from ages are being offered a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics and imaging technologies. Cardiac biomarkers and neuro biomarkers has brought a great revolution in disease diagnosis and prognosis.

Biomarkers are used in many other non-cancerous diseases. Some of the important ones are Alzheimer’s disease, Neurodegenerative diseases, cardiovascular diseases, and Huntington's disease

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences6th Pharmacogenomics Conference, September 12-14, 2016, Berlin, Germany; 5th Medicinal Chemistry Conference, December 05-07, 2016, Phoenix, USA; 2nd Biologic Drugs Conference, September 14-16, 2016 San Antonio, USA; 2nd Protein Engineering Conference, November 14-16, 2016, Atlanta, USA; 14th Global Experts Meeting on Nanomaterials, May 04-06, 2017, Dubai, UAE; American Society of Clinical Oncology; National Cancer Institute; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; 12th Annual Biomarkers & Diagnostics World Congress May 17-19, 2016, USA; UAE Cancer Congress, October 29-31,2 2015, UAE; 17th World Conference on Lung Cancer December, 04-07, 2016 Austria;  4th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17, 2016, Paris, France.

Track 6: Cell Free Biomarkers

Circulating biomarkers allow for the possibility of early, non-invasive detection of cancers. They also represent highly sensitive biomarkers of submissive disease and are capable of reflecting tumour affliction and cancer changing aspects. In the cancer biomarkers conferences, clinical, technical, and biological aspects of cell free biomarkers, and new technologies and techniques will be discussed. Special attention will be given to studies on clinical cases to further see the sights of the applications of these biomarkers and prospective of cell free biomarkers in disease diagnostics.

Circulatory biomarkers, precisely blood biomarkers have a wide area of research with development on various latest techniques, tools and tests for their detection and analysis, specifically aimed on targeted delivery.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences: 3rd Euro-Global Experts Meeting on Medical Case Reports, June 30-July 02, 2016 Valencia, Spain; 3rd Clinical Case Reports Meeting, September 02-05, 2017, Dubai, UAE; 3rd Experts Meeting on Medical Case Reports, May 09-10, 2016, New Orleans, USA; 2nd Clinical Trials Conference, August 22-24, 2016, Philadelphia, USA; 15th World Cardiothoracic Meeting, December 08-09, 2016 Philadelphia, USA; 25th AICR Research Conference, November 14-16, 2016, North Bethesda, USA; American Association for Cancer Research Annual Meeting April 16-20, 2016, USA; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; 3rd International Oncology Conference, September 10-11, 2016, UAE; 12th Annual Biomarkers & Diagnostics World Congress May 17-19, 2016, USA; Asia Pacific Lung Cancer Conference May, 13-16, 2016 Thailand;  4th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia.

Track 7: Predictive Cancer Biomarkers

Cancer biomarkers have become an indispensable part of cancer patient care. With discovery efforts on-going, the next phase towards conversion will involve validation and verification of clinical value. This includes the steps needed to manage the new treatment model from treating clinical symptoms to targeting genomic pathways. Focus will be given to the use of circulating tumour material to follow patients peripherally, both with known metastatic disease and post-surgery. In these Molecular Biomarkers conferences a special importance is given to this field.

Several challenges and solutions for NGS labs, including identifying and prioritizing biomarkers and patient stratification are the topics of high importance to be discussed under this track. Global Biomarkers conferences provide a great platform for to discuss these latest discoveries.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences14th Clinical Cardiology Conference, November 14-16, 2016, Orlando, USA; 14th Experimental Cardiology Conference, November 14-16, 2016, Orlando, USA; 9th Molecular Cardiology Conference, November 28-29, 2016, Sao Paulo, Brazil; 9th Cellular Cardiology Conference, November 28-29, 2016, Sao Paulo, Brazil; 2nd Pediatric Cardiology Conference, September 22-24, 2016, Las Vegas, USA; Association for International Cancer Research; Philippine Cancer Society; American Society of Clinical Oncology; 12th Annual Biomarkers Congress February 2017, Manchester, UK; 3rd International Oncology Conference, September 10-11, 2016, UAE; American Thoracic Society International Conference, May 13-18, 2016, USA; American Academy of Neurology Annual Meeting April 22-29, 2017, Boston, USA; 3rd Annual Drug Discovery USA Congress, 3-4 October 2016, San Diego , USA.

Track 8: Molecular Biomarkers Discovery

Biomarker discovery requires highly assured identification of a biomarker molecule with real-time quantitative information to indicate which proteins are altering to a statistically pertinent degree in response to disease. The discovery of molecular biomarkers has developed new strategies starting from the initial steps. In the first stage of biomarker discovery proceedings, investigation depends upon mass spectrometry techniques to make unbiased, semiquantitative analysis of changes between healthy and diseased states. The slope of probable molecular biomarkers generated in the discovery stage is to be further substantiated due to the high false positive rate. It is done through supplemental more targeted and quantitative mass spectrometry techniques, such as immuno affinity peptide enrichment.

Under this track, the latest trends in discovery and development of biomarkers and biomarker identification are discussed. There are many new strategies being fashioned in development of molecular biomarkers. In this section advancements of biomarkers in various sectors like clinical biomarkers, paediatric diseases biomarkers, and clinical analysis of NGS samples are covered.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences19th Interventional Cardiology Conference, August 21-23, 2017, Philadelphia, USA; 13th European Cardiology Congress, October 17-19, 2016, Rome, Italy; 10th World Congress on Neurology and Therapeutics, March 27-29, 2017, Madrid, Spain; 7th Neurologists Annual Meeting on Neurology, August 22-24, 2016 Vienna, Austria; 8th European Neurology Congress, September 21-23, 2016, Amsterdam, Netherlands; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; American Association for Cancer Research Annual Meeting April 16-20, 2016, USA; 12th Annual Biomarkers Congress February 2017, Manchester, UK; 2nd Biomarkers Conference September 19-20, 2016, UK; 3rd International Oncology Conference, September 10-11, 2016, UAE; Next Generation Dx Summit, August 23-24, 2016, Washington DC, USA; 17th World Conference on Lung Cancer December, 04-07, 2016 Austria.

Track 9: Biomarkers: Validation and Verification

The probable Molecular Biomarkers identified in discovery section need to be validated by using larger sample sets casing a broad section of patient troops. To avoid a potential bottleneck associated with taking a large number of candidates to validation, a verification step is engaged to monitor potential molecular biomarkers to ensure that only the top quality biomarkers from the discovery phase are taken into the expensive validation stage. A high throughput workflow with a minimum of sample preparation is required in the verification stage which provides both high specificity and high sensitivity. Furthermore, the confirmation that a particular methodology is suitable to be used in the biomarker validation phase is given in verification stage. These advanced strategies can be sited at molecular biomarkers conference.

The main areas covered under this track are assessment of drug response, advances in analysis, application of various tools in verification and validation of biomarkers and latest diagnostic techniques. All the latest techniques can be publicized in these biomarkers conferences.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences7th Neurologists Annual Meeting on Neuro Surgery, August 22-24, 2016 Vienna, Austria; Pediatric Neurology Conference, November 28-30, 2016, Valencia, Spain; 2nd Genetic Engineering Conference, November 14-16, 2016, Atlanta, USA; 8th Proteomics Conference, March 20-22, 2017, Philadelphia, USA; 2nd Biopharmaceutics Conference, September 14-16, 2016 San Antonio, USA; European Organisation for Research and Treatment of Cancer; Philippine Cancer Society; National Cancer Institute; 12th Annual Biomarkers & Diagnostics World Congress May 17-19, 2016, USA; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17, 2016, Paris, France; UAE Cancer Congress, October 29-31,2 2015, UAE; American Thoracic Society International Conference, May 13-18, 2016, USA; Asia Pacific Lung Cancer Conference May, 13-16, 2016 Thailand.

Track 10: Advances of Biomarker testing

Biomarker testing is a group of tests that looks for the molecular signs of health so that doctors can plan the best care. Biomarker testing can also be called as genetic testing or molecular testing. Molecular biomarkers, a foundation of precision oncology, are very important in management of breast cancer, gastro-esophageal cancer and non-small cell lung cancer. Testing practices are intensely deliberated, influencing diagnostic quality and affecting pathologists, oncologists and patients.

The advances in biomarker testing are mainly in the fields of genetic testing, cancers and other diseases in their diagnosis, treatment and imaging. In silico biomarkers, microRNA biomarkers and several other clinical biomarkers evolved in the recent researches have opened up the path for biomarker testing broader.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences6th Pharmacogenomics Conference, September 12-14, 2016, Berlin, Germany; 2nd Biologic Drugs Conference, September 14-16, 2016 San Antonio, USA; 2nd Protein Engineering Conference, November 14-16, 2016, Atlanta, USA; 4th Molecular Diagnostics Conference, September 22-24, 2016, Phoenix, USA; 14th Experimental Cardiology Conference, November 14-16, 2016, Orlando, USA; American Society of Clinical Oncology; National Cancer Institute; Association for International Cancer Research; 3rd Annual Drug Discovery USA Congress, 3-4 October 2016, San Diego , USA; 4th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Asia Pacific Lung Cancer Conference May, 13-16, 2016 Thailand; American Thoracic Society International Conference, May 13-18, 2016, USA; UAE Cancer Congress, October 29-31,2 2015, UAE.

Track 11: Biomarkers and Personalized Medicine

The ability to look at a patient individually will provide a more precise cancer diagnosis and specific treatment plan. The genetic information from individuals can then be used to effectively treat them, by finding the variations that can account for possible diseases. An individual’s genetic make-up also plays a large part in their extent of response to a certain treatment, and hence, having the knowledge of their genetic content can alter the type of treatment they receive. These approaches are intended to identify individualized patient benefits of therapies, minimize the risk of toxicity and reduce the cost of treatment.

In personalized medicine, biomarkers have a special place, which mends with cancer diagnosis, drug development and usage and cancer genomics. Challenges in these fields are an interesting topic to be discussed as there are radiant solutions emerging.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences3rd Experts Meeting on Medical Case Reports, May 09-10, 2016, New Orleans, USA; 19th Interventional Cardiology Conference, August 21-23, 2017, Philadelphia, USA; 7th Neurologists Annual Meeting on Neurology, August 22-24, 2016 Vienna, Austria; 5th Computer Aided Drug Designing Conference, December 05-07, 2016, Phoenix, USA; 7th Biomarkers Conference, December 05-07, 2016 Philadelphia, USA; 25th AICR Research Conference, November 14-16, 2016, North Bethesda, USA; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; American Association for Cancer Research Annual Meeting April 16-20, 2016, USA; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; American Academy of Neurology Annual Meeting April 22-29, 2017, Boston, USA; 17th World Conference on Lung Cancer December, 04-07, 2016 Austria; Next Generation Dx Summit, August 23-24, 2016, Washington DC, USA; 3rd International Oncology Conference, September 10-11, 2016, UAE.

Track 12: Companion Diagnostics

A medical device, which is often an in vitro device and which offers information that is important for the safe and operative use of a respective drug administration or biological product is called a companion diagnostic. These devices help to determine whether a specific therapeutic product’s benefits to a patient will be of more importance that can overshadow any possible serious side effects or risks to treat a patient. These molecular biomarkers conferences invite the latest technologies and techniques to be brought into light.

Partnership between cancer pharmaceutics and diagnostics is a sensitive relation as there are often miscommunications due to lack of knowledge on requirements and feasibilities. The strategies for Rx-Dx partnerships provide a good platform for sharing the knowledge. Development of In-vitro companion diagnostic devices and their commercialization is a rapidly budding area. These diagnostics are useful in the study of surgical oncology.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences:  2nd Mass Spectrometry Conference, July 20-22, 2016 Chicago, USA; 3rd Mass Spectrometry Conference, October 10-11, 2016, Kuala Lumpur, Malaysia; 5th Medicinal Chemistry Conference, December 05-07, 2016, Phoenix, USA; 14th Experimental Cardiology Conference, November 14-16, 2016, Orlando, USA; 9th Molecular Cardiology Conference, November 28-29, 2016, Sao Paulo, Brazil; ASCO Annual Meeting, June 03-07, 2016, Chicago, USA; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; Asia Pacific Lung Cancer Conference May, 13-16, 2016 Thailand;  4th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17, 2016, Paris, France; 12th Annual Biomarkers & Diagnostics World Congress May 17-19, 2016, USA.

Track 13: Biomarkers and Pharmacology

In the biomarker pipeline, the technologies that will enable the use of biomarkers in drug discovery and development vary depending on the research stage. The second stage, biomarker validation and clinical assay development, depends upon extremely sensitive and specific high-throughput immunoassays. The single greatest challenge in discovering biomarkers with clinical utility is the sensitivity and specificity necessary to determine that a biomarker is truly positive for disease or disease toxicodynamics, and can be used to detect deviations from normal. The molecular biomarkers conferences provide good exposure in drug discovery.

Biomarkers have special applications in the areas of translational medicine, clinical development and safety assessment where they are put through several stages of drug discovery, development and validation.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences:  10th World Congress on Neurology and Therapeutics, March 27-29, 2017, Madrid, Spain; Cancer Diagnostics Conference, June 13-15, 2016, Rome, Italy; 7th Neurologists Annual Meeting on Neuro Surgery, August 22-24, 2016 Vienna, Austria; 2nd Clinical Trials Conference, August 22-24, 2016, Philadelphia, USA; 3rd Euro-Global Experts Meeting on Medical Case Reports, June 30-July 02, 2016 Valencia, Spain; American Society of Clinical Oncology; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Organisation for Research and Treatment of Cancer; 17th World Conference on Lung Cancer December, 04-07, 2016 Austria; American Thoracic Society International Conference, May 13-18, 2016, USA; Next Generation Dx Summit, August 23-24, 2016, Washington DC, USA; UAE Cancer Congress, October 29-31,2 2015, UAE; 3rd International Oncology Conference, September 10-11, 2016, UAE.

Track 14: Molecular Imaging and Dynamics

Molecular Imaging is a cross-discipline which is an intersection of in vivo imaging and molecular biology. It facilitates the picturing of the cellular function and the supplement of the molecular process in biological processes without disturbing the living organisms. The various fields of study the Molecular Imaging brings life into are diagnosis of diseases such as cancer, cardiovascular diseases and neurological disorders. This technique also donates to the improvisation of the treatment of various diseases and disorders by adjusting the pre-clinical and clinical tests of new drugs. The molecular dynamics meetings are also expected to have a major economic impact due to very prior and more precise diagnosis.

Molecular imaging techniques using biomarkers have an important role in screening in various diseases particularly cancer screening using various new generation tools and technologies.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences:  Pediatric Neurology Conference, November 28-30, 2016, Valencia, Spain; 3rd Clinical Case Reports Meeting, September 02-05, 2017, Dubai, UAE; 2nd Biopharmaceutics Conference, September 14-16, 2016 San Antonio, USA; 14th Global Experts Meeting on Nanomaterials, May 04-06, 2017, Dubai, UAE; 4th Personalized Medicine Conference, September 22-24, 2016, Phoenix, USA; Philippine Cancer Society; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 03-07, 2016, Chicago, USA; 2nd Biomarkers Conference September 19-20, 2016, UK; 12th Annual Biomarkers & Diagnostics World Congress May 17-19, 2016, USA; 12th Annual Biomarkers Congress February 2017, Manchester, UK; 3rd International Oncology Conference, September 10-11, 2016, UAE; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17, 2016, Paris, France.

Track 15: Oncologists

The study of cancer is called Oncology. An oncologist is a person who specializes in the area of oncology and treating cancer patients. An oncologist manages care and treatment once a person is diagnosed with cancer.

In Germany there are about 2900 oncologists, and more than 8000 oncologists in USA, around 9500 oncologists in Europe and 1500 eminent oncologists from different parts of Asia.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences4th Molecular Diagnostics Conference, September 22-24, 2016, Phoenix, USA; 5th Translational Medicine Conference, November 28-30, 2016, San Francisco, USA; 2nd Molecular Medicine Conference, September 26-28, 2016, Orlando, USA; 14th Global Experts Meeting on Nanomaterials, May 04-06, 2017, Dubai, UAE; 5th Computer Aided Drug Designing Conference, December 05-07, 2016, Phoenix, USA; American Society of Clinical Oncology; European Organisation for Research and Treatment of Cancer; American Association for Cancer Research Annual Meeting April 16-20, 2016, USA; American Thoracic Society International Conference, May 13-18, 2016, USA; UAE Cancer Congress, October 29-31,2 2015, UAE; 2nd Biomarkers Conference September 19-20, 2016, UK;  4th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Asia Pacific Lung Cancer Conference May, 13-16, 2016 Thailand.

Track 16: Case Reports

A case report is an elaborated report of the symptoms, signs, disease diagnosis, treatment, and follow-up of an individual patient usually recorded in medical field. Case reports might comprehend a demographic profile of the patient, but typically mention any unusual or unique occurrences.

In this conference case reports on biomarker diagnostics, drug discovery and imaging are discussed in detail in relevance to molecular and cancer biomarkers. Cancer biomarkers conferences are a big platform to study case reports of these in precision. 

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences14th Experimental Cardiology Conference, November 14-16, 2016, Orlando, USA; 9th Molecular Cardiology Conference, November 28-29, 2016, Sao Paulo, Brazil; 7th Neurologists Annual Meeting on Neurology, August 22-24, 2016 Vienna, Austria; 14th Global Experts Meeting on Nanomaterials, May 04-06, 2017, Dubai, UAE; 7th Biomarkers Conference, December 05-07, 2016 Philadelphia, USA; National Cancer Institute; Philippine Cancer Society; European Organisation for Research and Treatment of Cancer; 12th Annual Biomarkers Congress February 2017, Manchester, UK; 12th Annual Biomarkers & Diagnostics World Congress May 17-19, 2016, USA; 2nd Biomarkers Conference September 19-20, 2016, UK; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17, 2016, Paris, France; 3rd International Oncology Conference, September 10-11, 2016, UAE.

Track 17: Entrepreneurs Investment Meet

Self-knowledge is the key ingredient in successful entrepreneurship. Molecular Biomarkers conferences aim to bring together all existing and promising bio entrepreneurs to share capabilities and present new novelties and challenges in biomarker community. Over a million companies are started in the world each year, in which about 5–10 of them are classified into high technology companies. All the Pharmaceutical and Biotech companies are majorly involved in the biomarkers production. Whirling ideas into business ventures is complex and the opportunity appreciation step is critical in new project creation. This idea in the entrepreneur's perception of the association between the invention and final product is converted into a business prototype that describes how the venture generate revenue or provide an suitable yield to the prospective investors. Clinical Research on biomarkers is multifaceted and rapidly expanding and requires an expert knowledge to comprehend the value of the advances and its competitive situation in the industry. Even though scientists are stereotypically the founders of biotech companies, studies indicate that the most effective start-ups are founded by a team which often has two to three individuals with mixed backgrounds like clinical research and Clinical Data Management along with considerable industry experience and a very strong market and product focus at establishment. This two day world-wide molecular and cancer biomarkers conferences will be a highly interactive forum that will bring experts in highly significant areas ranging from Biomarker discovery to latest diagnostics and Rx-Dx relationships. This global biomarker conference is sure a great platform to discuss the strategized development of industrial production of biomarkers.  

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences8th Proteomics Conference, March 20-22, 2017, Philadelphia, USA; 12th World Cancer Conference, September 26-28, 2016, London, UK; Cancer Diagnostics Conference, June 13-15, 2016, Rome, Italy; 2nd Mass Spectrometry Conference, July 20-22, 2016 Chicago, USA; 3rd Mass Spectrometry Conference, October 10-11, 2016, Kuala Lumpur, Malaysia; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 03-07, 2016, Chicago, USA; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17, 2016, Paris, France; 3rd International Oncology Conference, September 10-11, 2016, UAE; UAE Cancer Congress, October 29-31,2 2015, UAE; Next Generation Dx Summit, August 23-24, 2016, Washington DC, USA; American Thoracic Society International Conference, May 13-18, 2016, USA.

Conference Series LLC welcomes you to the '7th International Conference and Expo on Molecular & Cancer Biomarkers' to be held from September 15-16, 2016 in Berlin, Germany. Conference Series LLC organizes 3000+ Global events in conference series every year across  the globe with support from 1000+ more scientific societies and Publishes 700 Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board members.

The global cancer biomarkers market for 2007 was $3.6 billion and is expected to grow at a 6.3% CAGR (Compounded Annual Growth Rate) to reach up to $6.3 billion by 2016. A number of factors such as the rising demand for personalized medicine and companion diagnostics which in turn has raised the value of biomarkers in the healthcare sector. The global biomarkers market is expected to grow at a 18.5% CAGR from 2013 to 2018, to reach $40.8 billion by 2018. The cancer biomarker conferences are very much encouraged to spread the knowledge of advances in these days.

Molecular Biomarkers 2016 is organized around the theme: “Latest discoveries and innovations in the field of Molecular and Cancer Biomarkers”.

Molecular biomarkers, in the hands of clinical investigators, provide a dynamic and powerful approach to understanding the spectrum of diseases with obvious applications in analytic epidemiology, biomarkers and clinical research in disease prevention, diagnosis, and disease management. Molecular biomarkers have the additional potential to identify individuals susceptible to disease. There is a good scope to know more in this molecular biomarkers meeting. In the recent years, the information about cancer biomarkers has increased largely providing great scope for improving the management of cancer patients by improving the accuracy of detection and efficacy of treatment. Latest technological advancement has enabled the examination of many possible biomarkers and renewed interest in developing new biomarkers. All such developments can be evidenced in this molecular biomarker conference.

A comprehensive discussion of the significance of each biomarker like pharmacodynamics and toxicodynamics of protein biomarkers, analytical biomarkers, and epigenetic biomarkers is going to be held in this biomarkers congress. This conference also includes symposiums and workshop events.

Why to attend???

With members from around the world focused on learning about molecular and cancer biomarkers, and its advances; this is your best opportunity to reach the largest assemblage of participants from the biomarker community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in molecular and cancer biomarkers are hallmarks of this conference.

 Target Audience:

  • Biomarker research Students, Scientists
  • Biomarker Researchers
  • Cancer Researchers
  • Biomarker Faculty
  • Medical Colleges
  • Biomarker Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software developing companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies
  • Pharmaceutical Companies
  • Diagnostics Companies

 

The international market for cancer biomarkers was assessed to grow from $3.6 billion to $29.78 billion from 2007 by 2018 at an anticipated 14.60% CAGR (Compounded Annual Growth Rate) from 2011 when it was at $13.16 billion. Various factors such as the increasing demand for personalized medicine and companion diagnostics have enlarged the utility of biomarkers in the healthcare sector. 

Biomarkers are any measurable characteristics of an organism that reflect a particular physiological state. In medicine, biomarkers are used as an indicator to find the disease presence or its severity. Biomarker research has gone further to new drug therapies, companion diagnostics, molecular imaging and many other versatile fields. Demand for new biomarkers in different applications has boosted the biomarkers market.

Berlin is one of the leading biomarker research centres in Europe. Germany has good number of industries and research labs which work on biomarkers in various fields along with commercial production of them.

Members associated with Biomarker research:

Molecular biomarker research is widely encouraged all over the world. Experts from various cross disciplines like pathology, oncology, genomics, proteomics, doctors, pharmacologists, clinicians and technology development industries work in the field of biomarkers.

 

Hospitals associated with Biomarker research:

Various cancer research institutes and treatment facilities are involved in cancer biomarker research round the globe. There are about 1.906 in the world and 3 leading hospitals in Germany which work on biomarkers.

 

Societies associated with Biomarker research:

Molecular biomarkers are used in various disease diagnosis and treatment. Many prominent societies are also taking part in the biomarker research. Some of them are,

·           The ALS Association

·           Alzheimer's Association

·           Association for Molecular Pathology

·           The International Society Of Oncology and Biomarkers

·           American Society of Clinical Oncology

·           Cancer Research Society

·           National Cancer Institute at the National Institutes of Health

·           The Canadian Cancer Society

·           The Swedish Cancer Society

·           The British Associationfor Cancer Research

·           American Brain Tumor Association

·           German Society for Oncological Pharmacy

 

Industries associated with Biomarker research:

Biomarkers are not permitted to labs but actually produced in commercial scale by many industries and used in prognosis, diagnosis, treatment etc.

Companies which play an important role in biomarker market are,

·           Bayer AG

·           Boehringer Ingelheim

·           Epigenomics AG

·          ACS Biomarker B.V.

·          BioM AG Munich

Companies from others are,

·         Affymetrix, Inc

·         Agilent Technologies

·         Biomarker Pharmaceuticals, Inc.

·         Bristol-Myers Squibb Company

·         Roche Diagnostics Corporation

 

Universities associated with Biomarker research:

The majority of research is piloted in educational institutions by enthusiastic groups of researches in various places across the world.

The top universities in Berlin are,

·         University of Göttingen

·         Ludwig Maximilians University Munich

·         University of Nottingham

·         Humboldt University Berlin

·         University of Heidelberg

The top universities from rest of the world are,

·         Stanford University

·         Harvard University

·         University of California, Los Angeles

·         Yale University

·         Complutense University of Madrid

 

Market value on Biomarkers:

The present global market value of biomarkers is estimated to be $33 billion.

Nearly $7.32 billion is spent on the biotech industry in Europe in R&D and has $23.2 billion in revenue. About 20% of the total medicines marketed and almost 50% of all drugs in the pipeline, are all products of healthcare biotech. About 95,000 people are provided employment by European biotech industry contributing to EU policies. When compared to the other EU members, Germany accommodates maximum number of biotech-based companies which makes it the leading player in this market.

Market Growth

From $29.3 billion in 2013, the biomarkers market is anticipated to grow up to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.

In 2008 the German pharmaceuticals market valued $54.7 billion and is expected to reach an approximate value of $65 billion by 2020 at a CAGR of 1.4%. The medical device market of Germany was worth $18.9 billion in 2008 and is assessed to reach $34.4 billion in 2020 at a CAGR of 5.1%.

 

Products manufactured by the industries related to Biomarker Research and its market Value:

Numerous products are produced by industries for various uses like CTC technology, RNAi research tools, diagnostic tests and tools, separation systems and several other kits. These biomarker products have demanding market now. Some of them are having a great market value up to $17.1 billion and are expected to rise to $27.8 billion in near future.

 

Fund Allotment to Biomarker Research:

The Biomarker research has increased in double fold since it was first mentioned in 1973 in a research paper, also the funds allocated increased accordingly. NIH gave nearly $10.7 billion worth of grants to roughly 30,000 studies related to biomarker research, in which 10% are dedicated to just validation of biomarkers alone.

Other companies also funding the research with the increased market value. For example, a developer of novel prenatal screening tests company, Natera just announced an IPO with a $100 million goal. Natera’s revenue is $47.4 million, which raised from $27.2 million in 2014. Developers of novel cancer tests, Foundation Medicine, recently received an investment from Roche that increased the value of company over $2 billion.

Statistics of Physicians, Researchers and Academicians working on Biomarker Research:

The main individuals working on Biomarkers are academicians, researchers and physicians. There are plenty of people working on the biomarker research. In Berlin alone there are 148 prominent persons working on biomarkers. There are about 1000 people In Germany and about 32,515 eminent persons totally doing research related to biomarkers.

Biomarkers-2015

OMICS International hosted the “6th International Conference on Biomarkers & Clinical Research” (Biomarkers 2015) during August 31–September 02 at Toronto Airport Marriott Hotel, Toronto, Canada. The scientific meeting has laid path for the designing and development of research methodologies with the theme impact of “Lab to industry as bio-signatures to therapeutic discovery”.

Biomarkers 2015 was fortunate to acquire support from association and societies - Clinical Research Association of Canada (CRAC), Hypertension Canada, International Society for Cellular Therapy (ISCT), The Egyptian Biophysical Society and media partners -Biomarkers Profile Corporation, Gate2Biotech, The Technology Networks, Council of European Bio-Region, Oncology Education and Edinburgh Science Triangle.

The highlights of the meeting were the eponymous lectures, delivered by Dr. Claude Prigent, University of Rennes, France, Dr. Trevor G Marshall, Autoimmunity Research Foundation, USA,  Dr. Alain Moreau, Sainte-Justine University Hospital, Canada, Dr. Sergey Suchkov, I. M. Sechenov First Moscow State Medical University, Russia, Dr. Alexander M Buko, Human Metabolome Technologies, USA, Dr. Chee Gee See, Proteome Sciences, UK, Dr. Biswendu B Goswami, FDA Center for Food Safety and Applied Nutrition, USA.

Biomarkers 2015 held pre-conference workshop on August 1, 2015 in Mumbai University, India under the supervision of Prof. K. P. Mishra, Founder President of Society of Radiation Research, India. The workshop gathered 650+ participants inclusive of students, faculty, societies and industrial personnel.

The conference held 2 workshops under the supervision of Prof. Sergey Suchkov, I. M. Sechenov First Moscow State Medical University, Russia; Dr. Trevor G Marshall, Autoimmunity Research Foundation, USA and their team from Czech Republic and Prof. Youhe Gao, Beijing Normal University, China.


Past Reports  Proceedings  Gallery  

Biomarkers-2014

The 5th International Conference on Biomarkers & Clinical Research, the Biomarker-2014, was held during April 15-17, 2014 at Oxford, UK.

Biomarkers-2014 has taken up the scientific thoughts towards proving the importance of accurate diagnostics to be prevital towards the curing efficacy. The scientific meeting has laid path for the designing and development of research methodologies with the theme impact of “Diagnostic significance of the therapeutic bio-clinical molecule”.

The conference was greeted by the welcome message from President’s desk at the European Association for Predictive, Preventive and Personalised Medicine (EPMA), Brussels, EU. The support was extended through the PPPM workshop being conducted with the PPPM representatives from Russia, USA, Czech Republic and Saudi Arabia. The conference has gathered support from Everest Biotech, EuroScienceCon, Biomarkers Profile Corporation, ArrayMold, BioNews, Edinburgh Science Triangle, Biowebspin, The Technology Networks, European Biotechnology Thematic Network Association, Visiongain and Current Partnering as the media partners. In addition SCIENION has participated at the conference as Exhibitor at this conference.

The program highlights of the meeting were the eponymous lectures, delivered by Dr. Sergey Suchkov from I.M.Sechenov First Moscow State Medical University, Russia; Dr. Pavel Vodicka from Institute of Experimental Medicine, Czech Republic; Dr. Ondrej Topolcan from Charles University in Prague, Czech Republic; Dr. Claudio Nicolini from University of Genova, Italy and Dr. Claude Prigent from University of Rennes, France.


Past Reports  Gallery  

Biomarkers-2013
OMICS Group organized 4th International Conference on Biomarkers & Clinical Research, during July 15-17, 2013 at Philadelphia, USA under the theme of “Impact of Biomarkers Development in Health Diagnostics and Clinical Research”.

The conference was initiated with a series of invited lectures delivered by Dr. Jizu Yi from BD Diagnostics, USA; Dr. Yaping Tian from PLA General Hospital, China; Dr. Leticia Cano from Biomarker Profile Corporation, USA and Dr. Lawrence Greenfield from Affymetrix, USA.


Past Reports  Gallery  

Biomarkers-2012
The 3rd International Conference on Biomarkers & Clinical Research, organized by theOMICS Group was held on July 2-4, 2012 at Embassy Suites Las Vegas, USA under the theme of "Commercialization of Biomarkers". There were about 200 delegates representing 25 countries from different corners of the world who made this conference a big success in the field of Biomarkers and Clinical Research.

The conference was initiated with a series of invited lectures delivered by both Honorable Guests and members of the Keynote forum. The list includes Dr. Josip Blonder, Frederick National Laboratory for Cancer Research (NIH), USA; Dr. Marcel M. Daadi, Stanford University, USA; Dr. Ting-Chao Chou, Memorial Sloan-Kettering Cancer Center, USA; Dr. Jacob Kagan, National Cancer Institute, NIH, USA; Dr. Michael Sullivan, Worldwide Clinical Trials-Drug Development Solutions, USA; Dr. Hitoshi Sohma, Sapporo Medical University Center for Medical Education, Japan and Dr. Da Zhi Liu, University of California at Devis, USA. All the above mentioned Honourable Guests and Keynote speakers gave their energetic and fruitful contributions at Biomarkers-2012. All accepted abstracts have been indexed in OMICS Group Journal of Molecular Biomarkers & Diagnosis as a special issue.


Past Reports  Gallery  

Biomarkers-2011

OMICS Group organized 2nd World Congress on Biomarkers & Clinical Research in the most populous city of United States, the seat of Clark Country, on September 12-14, 2011. This annual conclave comprised of 10 Tracks and 44 sessions with a grand inaugural ceremony followed by a Keynote forum. The motive of this International conference was to emphasize on "Strategies and Developments in Biomarkers & Clinical Research."

This meeting brought together eminent scientists, scholars and entrepreneurs from across 30 countries in which many critical issues were discussed in depth to provide up-to-date information to the world. We take great pleasure to express our deep felt thanks to all the following keynote speakers:
Dr. Abdel Halim, Director, Daiichi-Sankyo Pharma Development, USA
Dr. Crispin R. Dass, Victoria University, Australia 
Dr. Jean Gabert, Université de la Méditerranée, France
Mr. Jeremy Warren, NanoSight Ltd, UK

OMICS Group will acknowledge with gratitude the support by FDA, Nanosight Ltd, AstraZeneca R&D, Biologics Consulting Group, Inc. Daiichi-Sankyo Pharma Development, etc. 


Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date September 15-16, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2
Poster Opportunity Available

Media Partners

Conferenceseries Destinations